title: The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI.
abstract: OBJECTIVE
  Secondary analyses of a previously conducted 1-year randomized controlled trial were performed to assess the application of responder criteria in patients with knee osteoarthritis (OA) using different sets of responder criteria developed by the Osteoarthritis Research Society International (OARSI) (Propositions A and B) for intra-articular drugs and Outcome Measures in Arthritis Clinical Trials (OMERACT)-OARSI (Proposition D).
  
  
  METHODS
  Two hundred fifty-five patients with knee OA were randomized to "appropriate care with hylan G-F 20" (AC+H) or "appropriate care without hylan G-F 20" (AC). A patient was defined as a responder at month 12 based on change in Western Ontario and McMaster Universities Osteoarthritis Index pain and function (0-100 normalized scale) and patient global assessment of OA in the study knee (at least one-category improvement in very poor, poor, fair, good and very good). All propositions incorporate both minimum relative and absolute changes.
  
  
  RESULTS
  Results demonstrated that statistically significant differences in responders between treatment groups, in favor of hylan G-F 20, were detected for Proposition A (AC+H=53.5%, AC=25.2%), Proposition B (AC+H=56.7%, AC=32.3%) and Proposition D (AC+H=66.9%, AC=42.5%). The highest effectiveness in both treatment groups was observed with Proposition D, whereas Proposition A resulted in the lowest effectiveness in both treatment groups. The treatment group differences always exceeded the required 20% minimum clinically important difference between groups established a priori, and were 28.3%, 24.4% and 24.4% for Propositions A, B and D, respectively.
  
  
  CONCLUSIONS
  This analysis provides evidence for the capacity of OARSI and OMERACT-OARSI responder criteria to detect clinically important statistically detectable differences between treatment groups.
authors.affiliation: CONROD, Faculty of Health Sciences, The University of Queensland, Brisbane, Queensland, Australia. nbellamy@medicine.uq.edu.au
authors.forename: Nicholas
authors.initials: N
authors.lastname: Bellamy
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Bell
authors.forename: Charlie H
authors.initials: CH
authors.lastname: Goldsmith
authors.forename: Dan
authors.initials: D
authors.lastname: Pericak
authors.forename: Valery
authors.initials: V
authors.lastname: Walker
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Raynauld
authors.forename: George W
authors.initials: GW
authors.lastname: Torrance
authors.forename: Peter
authors.initials: P
authors.lastname: Tugwell
authors.forename: Richard
authors.initials: R
authors.lastname: Polisson
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement / Q000379:methods; D011446:Prospective Studies; D012720:Severity of Illness Index; D012955:Societies, Medical; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; C049816:hylan; D006820:Hyaluronic Acid